Health Condition 1: N920- Excessive and frequent menstruation with regular cycle
Conditions
Interventions
None listed
Sponsors
Dr Pragya Mulewa
Eligibility
Inclusion criteria
Inclusion criteria: 1. Woman aged between 18 to 45 years willing to participate. 2. Patients having complaints of HMB (heavy menstrual bleeding) (PBAC Score more than 100) for at least three consecutive menstrual cycles. 3. Patient having blood loss more than 80 ml per menstrual cycle (according to FIGO concept of AUB). 4. Patients using more than 8 large sized fully soaked pads OR patients using more than 17 normal sized fully soaked pads per menstrual cycle. 5. Patients who changes pad per 2 hour during her menstrual cycle. 6. Patients having cyclical excessive per vaginal bleeding, with or without clots during menses. 7. Patients having haemoglobin 8g per dl or more.
Exclusion criteria
Exclusion criteria: 1. Post menopausal bleeding. 2. Bleeding associated with intrauterine contraceptive devices, oral contraceptive pills. 3. Patients with pelvic inflammatory disease (PID), uterine polyps, or uterine fibroids more than 5cm 4. Incomplete abortion. 5. Known case of Thyroid dysfunction. 6. Known cases of Systemic illnesses like hypertension, diabetes mellitus, renal disease, and liver disease. 7. Known case of Inherited or acquired bleeding disorders and coagulatory defects. 8. Patients with haemoglobin level less than 8g per dl. 9. Patients having bleeding for more than 8 days. 10. Patients having blood loss of more than 200ml per menstrual cycle.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in menstrual blood loss measured with the help of PBAC score. Timepoint: 1. Baseline (Day 0 before treatment). 2. After 4 weeks of treatment (during first follow-up menstrual cycle). 3. After 8 weeks of treatment (during second follow-up menstrual cycle). 4. After 12 weeks of treatment (during third follow-up menstrual cycle). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Improvement in fatigue. 2. Improvement in weakness. 3. Improvement in patient complianceTimepoint: 1. Baseline (Day 0 before treatment). 2. After 4 weeks of treatment (during first follow-up menstrual cycle). 3. After 8 weeks of treatment (during second follow-up menstrual cycle). 4. After 12 weeks of treatment (during third follow-up menstrual cycle). | — |
Countries
India
Contacts
Public ContactDr Prashant Fawade
Parul institute of ayurved and Research
Outcome results
None listed